Chemotherapy in advanced nonsmall cell lung cancer: Indication, intensity, and duration

Richard Booton; Nicholas Thatcher

doi:10.1097/00001622-200203000-00009

Chemotherapy in advanced nonsmall cell lung cancer: Indication, intensity, and duration

Richard Booton, Nicholas Thatcher

Research output: Contribution to journal › Article › peer-review

Abstract

Platinum-based combination and single-agent chemotherapy have become accepted as treatments for locally advanced and metastatic nonsmall cell lung cancer as a consequence of improved survival, quality of life, and symptom control compared with best supportive care. However, it is clear that a therapeutic plateau has been reached with current combinations requiring a re-evaluation of strategies to improve clinical outcomes. Dose intensification may offer one way in which to achieve better results, as may extension of the duration of treatment. The evidence suggests that dose intensification is a useful tool, and that its use in combination with markers of treatment duration and cumulative dose may help to maximize results from current active drug combinations. © 2002 Lippincott Williams & Wilkins, Inc.

Original language	English
Pages (from-to)	191-198
Number of pages	7
Journal	Current opinion in oncology
Volume	14
Issue number	2
DOIs	https://doi.org/10.1097/00001622-200203000-00009
Publication status	Published - 2002

Keywords

therapeutic use: Antineoplastic Agents
drug therapy: Carcinoma, Non-Small-Cell Lung
Combined Modality Therapy
Humans
drug therapy: Lung Neoplasms
Randomized Controlled Trials as Topic
Time Factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00001622-200203000-00009

Cite this

@article{a5e1e8ade71640ffa704c3ac4ac8f8bb,

title = "Chemotherapy in advanced nonsmall cell lung cancer: Indication, intensity, and duration",

abstract = "Platinum-based combination and single-agent chemotherapy have become accepted as treatments for locally advanced and metastatic nonsmall cell lung cancer as a consequence of improved survival, quality of life, and symptom control compared with best supportive care. However, it is clear that a therapeutic plateau has been reached with current combinations requiring a re-evaluation of strategies to improve clinical outcomes. Dose intensification may offer one way in which to achieve better results, as may extension of the duration of treatment. The evidence suggests that dose intensification is a useful tool, and that its use in combination with markers of treatment duration and cumulative dose may help to maximize results from current active drug combinations. {\textcopyright} 2002 Lippincott Williams & Wilkins, Inc.",

keywords = "therapeutic use: Antineoplastic Agents, drug therapy: Carcinoma, Non-Small-Cell Lung, Combined Modality Therapy, Humans, drug therapy: Lung Neoplasms, Randomized Controlled Trials as Topic, Time Factors",

author = "Richard Booton and Nicholas Thatcher",

year = "2002",

doi = "10.1097/00001622-200203000-00009",

language = "English",

volume = "14",

pages = "191--198",

journal = "Current opinion in oncology",

issn = "1040-8746",

publisher = "Lippincott Williams & Wilkins",

number = "2",

}

TY - JOUR

T1 - Chemotherapy in advanced nonsmall cell lung cancer: Indication, intensity, and duration

AU - Booton, Richard

AU - Thatcher, Nicholas

PY - 2002

Y1 - 2002

N2 - Platinum-based combination and single-agent chemotherapy have become accepted as treatments for locally advanced and metastatic nonsmall cell lung cancer as a consequence of improved survival, quality of life, and symptom control compared with best supportive care. However, it is clear that a therapeutic plateau has been reached with current combinations requiring a re-evaluation of strategies to improve clinical outcomes. Dose intensification may offer one way in which to achieve better results, as may extension of the duration of treatment. The evidence suggests that dose intensification is a useful tool, and that its use in combination with markers of treatment duration and cumulative dose may help to maximize results from current active drug combinations. © 2002 Lippincott Williams & Wilkins, Inc.

AB - Platinum-based combination and single-agent chemotherapy have become accepted as treatments for locally advanced and metastatic nonsmall cell lung cancer as a consequence of improved survival, quality of life, and symptom control compared with best supportive care. However, it is clear that a therapeutic plateau has been reached with current combinations requiring a re-evaluation of strategies to improve clinical outcomes. Dose intensification may offer one way in which to achieve better results, as may extension of the duration of treatment. The evidence suggests that dose intensification is a useful tool, and that its use in combination with markers of treatment duration and cumulative dose may help to maximize results from current active drug combinations. © 2002 Lippincott Williams & Wilkins, Inc.

KW - therapeutic use: Antineoplastic Agents

KW - drug therapy: Carcinoma, Non-Small-Cell Lung

KW - Combined Modality Therapy

KW - Humans

KW - drug therapy: Lung Neoplasms

KW - Randomized Controlled Trials as Topic

KW - Time Factors

U2 - 10.1097/00001622-200203000-00009

DO - 10.1097/00001622-200203000-00009

M3 - Article

SN - 1040-8746

VL - 14

SP - 191

EP - 198

JO - Current opinion in oncology

JF - Current opinion in oncology

IS - 2

ER -

Chemotherapy in advanced nonsmall cell lung cancer: Indication, intensity, and duration

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this